Ligand Pharmaceuticals (FRA:LGDN) Tariff Resilience Score: 8/10 (As of Jul. 05, 2026)


FRA:LGDN Ligand Pharmaceuticals Inc FRA:LGDN
73 GF Score
Price €280.00
GF Value €155.17
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Ligand Pharmaceuticals Tariff Resilience Score?

Ligand Pharmaceuticals FRA:LGDN +5.26% 73 Tariff Resilience Score is 8 as of Jul. 05, 2026. GuruFocus rates FRA:LGDN with a GF Score™ of 73/100 and a GF Value™ of €155.17 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,369 Biotechnology companies, Ligand Pharmaceuticals ranks better than 98.69% on this metric.

Ligand Pharmaceuticals has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Ligand Pharmaceuticals has Ligand Pharmaceuticals has low tariff exposure due to its focus on pharmaceuticals and biotech, industries often exempt from tariffs. Its global partnerships and licensing model provide resilience, though any raw material imports could face minor impacts. The company is well-positioned to adapt.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Ligand Pharmaceuticals might have Highly Resilient.

Ligand Pharmaceuticals  (FRA:LGDN) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Ligand Pharmaceuticals Tariff Resilience Score Related Terms

FRA:LGDN vs DFTX, CGON, XENE: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Ligand Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ligand Pharmaceuticals Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ligand Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Ligand Pharmaceuticals's Tariff Resilience Score falls into.


FRA:LGDN
73GF Score
Ligand Pharmaceuticals Inc FRA:LGDN
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Ligand Pharmaceuticals (FRA:LGDN) has a Tariff Resilience Score of 8 as of Jul. 05, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Ligand Pharmaceuticals ranks #18 out of 1369 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Ligand Pharmaceuticals' Tariff Resilience Score too high?
Ligand Pharmaceuticals' current Tariff Resilience Score is 8. The Biotechnology industry median Tariff Resilience Score is 4.00. Ligand Pharmaceuticals' value of 8 is 100% above this industry median. Based on the distribution chart, Ligand Pharmaceuticals ranks #18 out of 1369 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ligand Pharmaceuticals has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ligand Pharmaceuticals' Tariff Resilience Score compare to DFTX and CGON?
According to the Biotechnology industry distribution chart, Ligand Pharmaceuticals ranks #18 out of 1369 companies for Tariff Resilience Score. This places Ligand Pharmaceuticals in the top 1% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Ligand Pharmaceuticals' value of 8 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,369 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ligand Pharmaceuticals's current Tariff Resilience Score of 8 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ligand Pharmaceuticals's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ligand Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ligand Pharmaceuticals (FRA:LGDN) is currently considered Significantly Overvalued. The stock's GF Value™ is €155.17, compared to a current price of €280.00 — trading 80.4% above its estimated fair value. The current Tariff Resilience Score is 8 and 100% above the Biotechnology industry median of 4.00. Ligand Pharmaceuticals' overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Ligand Pharmaceuticals (FRA:LGDN), the current Tariff Resilience Score is 8 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ligand Pharmaceuticals (FRA:LGDN) Overvalued in 2026?

Based on GuruFocus' analysis, Ligand Pharmaceuticals stock appears to be overvalued. The current stock price of €280.00 is trading 80.4% above its estimated GF Value™ of €155.17. GuruFocus considers Ligand Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:LGDN:

  • Tariff Resilience Score: 8
  • GF Value™: €155.17 vs. price of €280.00 (80.4% above fair value)
  • GF Score™: 73/100 with 5 warning signs
  • Industry Position: 100% above the Biotechnology median (#18 of 1369)

No single metric tells the full story. See the FRA:LGDN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ligand Pharmaceuticals Business Description

Other Exchanges LGND:USA
Address 555 Heritage Drive, Suite 200, Jupiter, FL, USA, 33458
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
73GF Score

Get the complete analysis for FRA:LGDN

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€280.00
Price
€155.17
GF Value